<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804348</url>
  </required_header>
  <id_info>
    <org_study_id>F-7-32.2-1</org_study_id>
    <secondary_id>0096-12-NHR</secondary_id>
    <nct_id>NCT01804348</nct_id>
  </id_info>
  <brief_title>AL-SENSE 1-Step - Determination of Product Specificity</brief_title>
  <acronym>ROM</acronym>
  <official_title>AL-SENSE 1-Step - Determination of Product Specificity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Common Sense</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Common Sense</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical diagnosis of amniotic fluid leak will be determined, according the hospital standard&#xD;
      procedure, using pooling test and/or sterile speculum examination and /or pH test, and&#xD;
      AmniSure, N-Dia, Inc. (immunoassay for diagnosis of ruptured fetal membranes (ROM)). Amniotic&#xD;
      fluid leak test, using the AL- SENSE 1-Step device, will be considered positive in case of&#xD;
      presence of a blue or green or grey stain on a yellow background of the AL-SENSE 1-Step, as&#xD;
      observed by the patient and the clinician (positive/negative).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women arriving at the hospital and reporting unidentified wetness (undetermined&#xD;
      whether they sense amniotic fluid leakage or urinary incontinence) will receive a single&#xD;
      AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness. The clinician will&#xD;
      explain the proper use and handling of the AL-SENSE 1-Step and how to read the result.&#xD;
&#xD;
      In each case, the subject and the clinician/midwife (non bias to the hospital standard&#xD;
      procedure results) will be required to read and record any occurrence of color change of the&#xD;
      AL-SENSE 1-Step immediately after removing the test to mark if it changes color to blue or to&#xD;
      green or to grey on the designated form.&#xD;
&#xD;
      The non bias physician, who is not aware to the AL-SENSE 1-Step result (other than the&#xD;
      clinician/midwife who records the AL-SENSE 1-Step results) will perform a diagnosis tests for&#xD;
      amniotic fluid leak detection, according to the hospital standard procedure.&#xD;
&#xD;
      The investigator will compare the AL-SENSE 1-Step results reading of the patient to the&#xD;
      clinical diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amniotic fluid leaks</measure>
    <time_frame>up to 12 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>PREMATURE RUPTURE OF MEMBRANES</condition>
  <arm_group>
    <arm_group_label>AL-SENSE 1-Step</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AL-SENSE 1-Step</intervention_name>
    <description>a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.</description>
    <arm_group_label>AL-SENSE 1-Step</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. AgE 18 years OR GREATER.&#xD;
&#xD;
          2. Subject who will sign the informed consent form.&#xD;
&#xD;
          3. Subject who arrive at the obstetric department reporting a feeling of vaginal wetness&#xD;
             feeling (undetermined whether she sense amniotic fluid leakage or urinary&#xD;
             incontinence).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects that have had sexual relations within the last 12 hours.&#xD;
&#xD;
          2. Subject is unable or unwilling to cooperate with study procedures.&#xD;
&#xD;
          3. Subject is currently participating in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Bornstain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Galilee Hospital Nahariya, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Galilee Hospital</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacob Bornstein, MD</last_name>
      <phone>+972-4-9107720</phone>
      <email>Jacob.Bornstein@naharia.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Jacob Bornstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>February 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PROM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

